The cGMP certification, in particular, ensures that the product is consistently produced and controlled according to quality standards
(November 2015)
In a Phase 2b study in people with type 2 diabetes and obesity over 54 weeks, treatment with cotadutide at doses of 100-300 g daily improved some non-invasive markers of NAFLD such as transaminase levels, the FIB-4 index, fatty liver disease fibrosis score (NFS) and fatty liver index (FLI) but fatty liver disease was not assessed directly with liver biopsy
Researchers have documented the safety profile observed in published Phase 2 research as predominantly gastrointestinal effects (nausea, diarrhoea, vomiting) typical of the incretin class, occurring most prominently during dose escalation and tending to decline with continued exposure (PMID 39515565, PMID 41785010)
LIVV Natural is built differently
Although LSECs account for only about three per cent of liver cell volume, they proved to be the key driver of semaglutides liver benefits
